Checkmate Pharmaceuticals Inc.
Industry: Biological Product (except Diagnostic) Manufacturing
CMPI Cash Flow
|Cashflowfinancing_Auditor's Report (aud. name & aud. op.)||N/A||UE||UQ||UE|
|Cashflowfinancing_Auditor's name (aud. name & aud. op.)||N/A||KPMG LLP||KPMG LLP||KPMG LLP|
|Cashflowfinancing_Cash at beginning of period||22 M||12 M||4 M||43 M|
|Cashflowfinancing_Cash at end of period||12 M||4 M||43 M||51 M|
|Cashflowfinancing_Cash from disc. financing activities||0||0||0||0|
|Cashflowfinancing_Effect of exchange rate changes||0||0||0||0|
|Cashflowfinancing_Issuance of capital stock||11 M||19 M||150 M||146000|
|Cashflowfinancing_Issuance of debt||0||0||10 M||0|
|Cashflowfinancing_Net cash from financing activities||11 M||19 M||160 M||146000|
|Cashflowfinancing_Net change in cash & cash equivalents||-9 M||-8 M||39 M||8 M|
|Cashflowfinancing_Other financing charges net||0||0||0||0|
|Cashflowfinancing_Payment of cash dividends||0||0||0||0|
|Cashflowfinancing_Repayment of debt||0||0||0||0|
|Cashflowfinancing_Repurchase of capital stock||0||0||0||0|
|Cashflowinvesting_Cash from disc. investing activities||0||0||0||0|
|Cashflowinvesting_Net cash from investing activities||0||0||-83 M||61 M|
|Cashflowinvesting_Other investing changes net||0||0||0||0|
|Cashflowinvesting_Purchase of Float term investments||0||0||0||0|
|Cashflowinvesting_Purchase of property plant & equipment||0||0||0||-843000|
|Cashflowinvesting_Purchase of short term investments||0||0||0||0|
|Cashflowinvesting_Sale of Float term investments||0||0||0||0|
|Cashflowinvesting_Sale of property plant equipment||0||0||0||0|
|Cashflowinvesting_Sale of short term investments||0||0||0||0|
|Cashflowoperating_(Increase) Decrease in inventories||0||0||0||0|
|Cashflowoperating_(Increase) Decrease in other current assets||0||0||0||-4 M|
|Cashflowoperating_(Increase) Decrease in other current liabilities||-24000||1 M||2 M||416000|
|Cashflowoperating_(Increase) Decrease in other working capital||0||0||0||0|
|Cashflowoperating_(Increase) Decrease in payables||118000||606000||63000||1 M|
|Cashflowoperating_(Increase) Decrease in prepaid expenses||149000||-506000||-6 M||4 M|
|Cashflowoperating_(Increase) Decrease in receivables||0||0||0||0|
|Cashflowoperating_Amortization of intangibles||0||0||0||0|
|Cashflowoperating_Deferred income taxes||N/A||N/A||N/A||N/A|
|Cashflowoperating_Extraordinary (gains) losses||0||0||0||0|
|Cashflowoperating_Net cash from continuing operations||-20 M||-27 M||-38 M||-54 M|
|Cashflowoperating_Net cash from discontinued operations||0||0||0||0|
|Cashflowoperating_Net cash from operating activities||-20 M||-27 M||-38 M||-54 M|
|Cashflowoperating_Net income (loss)||0||0||0||0|
|Cashflowoperating_Operating (gains) losses||0||0||0||35000|
|Cashflowoperating_Other non-cash items||0||-400000||83000||0|
Rush Enterprises Inc. Class B Common Stock
Booz Allen Hamilton Holding Corporation
BWX Technologies Inc.
Ritchie Bros. Auctioneers Incorporated
Ituran Location and Control Ltd.
General Mills Inc.
ConAgra Brands Inc.
Agree Realty Corporation
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to email@example.com to avail the extention
From all of us at MarketXLS, thank you!